Search Results

You are looking at 1 - 10 of 13 items for :

  • sustainability x
  • Laboratory Medicine x
Clear All
Open access

Ming-hui Li, Yao Xie, Yao Lu, Guo-hua Qiu, Lu Zhang, Ge Shen, Li-wei Zhuang, Ju-long Hu, Jian-ping Dong, Cai-qin Mu, Lei-ping Hu, Li-jun Chen, Xing-hong Li, Min Yang, Yun-zhong Wu, Hui Zhao, Shu-jing Song, Jun Cheng and Dao-zhen Xu

. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46:1688-1694. 24. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150:528-540. 25. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological

Open access

Zhu Chen, Yi-lan Zeng, Li Wang, Rong Hu, Yan Wang, Yu-zhen Tang, Li Zhu and Bei Wu

YM, et al. Randomized, open-label and active controlled study of PEGIFNα- 2a in the treatment of chronic hepatitis C in China (in Chinese). J Infect Dis 2004;22(4):221-224. 4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009;461:399-401. 5. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virological response in patients with hepatitis

Open access

Hanyu Wang and Weihong Kuang

multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation J. Clin. Oncol. 2016 34 24 2843 2850 [48] Ball, L.M., Bernardo, M.E., Roelofs, H., van Tol, M.J., Contoli, B., Zwaginga, J.J., et al., Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease, Br. J. Haematol., 2013, 163(4), 501

Open access

Jian-ming Zheng, Ming-quan Chen, Meng-qi Zhu, Ning Li, Qian Li, Xin-yu Wang, Chong Huang and Guang-feng Shi

peginterferon alfa-2a for HBeAgpositive chronic hepatitis B. Hepatology 2008;47:428-434. 5 Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-1157. 6 Stetson DB, Medzhitov R. Type Ⅰ interferons in host defense. Immunity 2006;25:373-381. 7 Qureshi H, Arif A, Ahmed W, Alam SE, Mujeeb SA, Haq Nu, et al. Role of interferon antibody in

Open access

Consensus. Chinese Consensus on Combination Therapy of Chronic Hepatitis B

Professional Staff Committee of Combination Therapy of Chronic Hepatitis B

Jun Cheng

. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953. 30 Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434. 31 Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained

Open access

Hong Du, Jing Li, Hai-tao Yu, Wei Jiang, Ye Zhang, Jun-ning Wang, Ping-zhong Wang and Xue-fan Bai

):2227-2236. 4. Schmaljohn CS, Hasty SE, Dalrymple JM, LeDuc JW, Lee HW, von Bonsdorff CH, et al. Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome. Science 1985; 227(5690):1041-1044. 5. Welzel TM, Zeier M, Darai G, Ritz E. Hantavirus infection--new threats by an old virus. Nephrol Dial Transplant 1998; 13(11): 2731-2733. 6. Ma Y, Liu B, Yuan B, Wang J, Yu H, Zhang Y, et al. Sustained high level of serum VEGF at convalescent stage contributes to the renal recovery after HTNV infection in patients with

Open access

Hang Zhang

Agents Chemother, 2008, 52(10): 3617-3632. 19 Dandri M, Petersen J. Chimeric mouse model of hepatitis B virus infection. J Hepatol, 2012, 56(2): 493-495. 20 Ilan E, Burakova T, Dagan S, et al . The hepatitis B virustrimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology, 1999, 29(2): 553-562. 21 Ohashi K, Marion PL, Nakai H, et al . Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med, 2000, 6(3): 327-331. 22

Open access

Chao Wen, Xiaoyu Wang, Taisheng Chen, Hongying Ruan and Peng Lin

pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med, 2004, 169(7): 860-867. 21 Zhao S, Liu H, Han D, et al. Expression of middle ear nuclear factor κB in exudative otitis media of rats induced by allergen. Lin Chuang Er Bi Hou Tou Jing Wai Ke Za Zhi, 2008, 22: 751. 22 Kariya S, Okano M, Hattori H, et al. TH1/TH2 and regulatory cytokines in adults with otitis media with effusion. Otol Neurotol, 2006, 27(8): 1089-1093. 23 Skotnicka B, Stasial-Barmuta A, Hassmann-Poznanske E, et a

Open access

Jun Cheng, Min Quan, Min Li, Shun-ai Liu and Qi Wang

pegylated interferon- α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res 2010;40:269-277. 41 Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-1897. 42 Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferonα-2a and adefovir. J Gastroenterol Hepatol

Open access

Ryota Masuzaki and Masao Omata

Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-181. 18 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferonalpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055. 19 Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524. 20 Manns